NCT04731103View on ClinicalTrials.gov

Inhibition of Reverse Transcription in Aicardi-Goutières Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

August 24, 2022

Primary Completion Date

March 11, 2024

Study Completion Date

March 11, 2024

Conditions
Aicardi-Goutières Syndrome
Interventions
DRUG

Abacavir (ABC)

Tablets or oral solution

DRUG

Lamivudine (3TC)

Tablet or oral solution

DRUG

Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT)

Tablet or oral solution

Trial Locations (1)

Unknown

Yanick Crow, Edinburgh

Sponsors

Collaborators (1)

Medical Research Council
All Listed Sponsors
collaborator

NHS Lothian

OTHER_GOV

collaborator

Medical Research Council

OTHER_GOV

lead

University of Edinburgh

OTHER